

Eyetech Pharmaceuticals (New York) has announced that **Anthony P. Adamis**, associate professor of ophthalmology at the Harvard Medical School, has joined the company as senior vice president of research and chief scientific officer. Dr. Adamis has been affiliated with Eyetech since its inception in April 2000, as a member of its scientific advisory board and director of preclinical research.

Biogen (Cambridge, MA) has announced the appointment of **Christine Carberry** as vice president, program and alliance management. Ms. Carberry joined Biogen in 1984, and was most recently the program executive of the LFA-1 program, which is developing orally active small-molecule antagonists that work to inhibit T-cell migration and activation that can lead to inflammatory diseases. In her new position, she will oversee the company's development programs in the areas of autoimmune diseases, neurodegeneration, oncology, and fibrosis.

EmerGen (Salt Lake City, UT) has announced the appointment of **Scott C. Chappel** to its board of directors. Dr. Chappel is currently executive vice president, research and technology at Dyax.

Matthew Fust has joined Perlegen Sciences (Mountain View, CA) in the newly created role of chief financial officer. Previously, he was senior vice president and CFO for ALZA until its acquisition by Johnson & Johnson.

Elan (Dublin) has announced the resignation of **Donal Geaney** as chairman, chief executive officer, and a director of the company. In addition, **Thomas Lynch** has stepped down from the board and his position as vice chairman. Elan's board of directors has elected **Garo Armen** as chairman of the board of directors and chairman of a five-person executive committee, and has initiated an immediate search for a CEO. Dr. Armen, a director of Elan since 1994, is chairman and CEO of Antigenics.

GenPath Pharmaceuticals (Cambridge, MA) has announced the appointments of **Tuan Ha-Ngoc** as president and CEO and **Steven Clark** as chief scientific officer. Mr. Ha-Ngoc previously served as executive vice president at Genetics Institute. After its acquisition by American Home Products (now Wyeth), he assumed the position of corporate vice president. Dr. Clark was senior vice president of the combined discovery organizations of Wyeth and Genetics Institute, as well as a founding scientist at GI in 1981.

William J. Knight, formerly chief financial officer of Zycos and NMT Medical, has

joined Anika Therapeutics (Woburn, MA) in the same position. He replaces Douglas R. Potter, who left the company earlier this year.



Ian A. McDonald has been named vice president of drug discovery for Structural GenomiX (San Diego, CA). Dr. McDonald has held senior chemistry positions in biotechnology and pharmaceutical companies, most recently as vice president of drug discovery for Structural Bioinformatics.

Gerard J. Michel has been named vice president, corporate development of NPS Pharmaceuticals (Salt Lake City, UT). Mr. Michel comes to NPS after six years at the consulting firm of Booz-Allen & Hamilton.

Idenix Pharmaceuticals (Cambridge, MA) has announced the appointment of **David M. Shlaes** to the position of executive vice president, R&D. Dr. Shlaes was formerly vice president, infectious disease with Wyeth Research, a



David Shlaes

division of Wyeth. In addition, the company has also elected Ambassador **Charlene Barshefsky** to its board of directors. Ambassador Barshefsky served in the Clinton administration as the United States trade representative from 1997 to 2001, and is currently senior international partner at the law firm of Wilmer, Cutler & Pickering.

Jeffrey Trent, scientific director of the National Genome Research Institute at the National Institutes of Health, has agreed to assume the role of president and chief scientific officer for the newly named Translational Genomics Research Institute (previously known as the Arizona Bioscience and Biomedicine Institute, or ABBi; Phoenix, AZ).

Gary Woodnutt has been appointed senior vice president, pharmaceutical R&D and **Lee R. McCracken** has been appointed senior vice president, pharmaceutical business development at Diversa (San Diego, CA). Dr. Woodnutt joins Diversa from GlaxoSmithKline, where he served most recently as vice president of microbiology. Mr. McCracken was formerly president & chief business officer at GenStar Therapeutics.

OraPharma (Warminster, PA) has announced that **David P. Wright**, president and chief business officer of Guilford Pharmaceuticals, has been appointed to serve on the board of directors at OraPharma.